Status:
UNKNOWN
Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units
Lead Sponsor:
Université Catholique de Louvain
Conditions:
Pharmacokinetics
Anti-Bacterial Agents
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Antibiotics are still most often administered on an empiric fashion, as defined for the general population with dosages only adapted based on weight and renal and/or hepatic functions. As a result, se...
Detailed Description
1. Background, Literature Survey and Justification of The Study 1.1. Introduction β-lactams efficacy depends primarily from the time interval during which the plasma concentration remains abov...
Eligibility Criteria
Inclusion
- Patients with suspicion or documentation of of an infection requiring intravenous antibiotic therapy (this includes any patient admitted to the Intensive Care Unit for an infection (or developing an infection) that calls for administration of temocillin, ceftriaxone or meropenem).
Exclusion
- Patients allergic to β-lactams
- IgE-mediated hypersensibility to penicillins
- any biological abnormality that the attending physician considers as susceptible to delay or perturb in a significant manner the interpretation of the trial
- lack of accepted informed consent
- patient with therapeutic limitations
Key Trial Info
Start Date :
March 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03440216
Start Date
March 15 2018
End Date
December 15 2022
Last Update
May 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques universitaires Saint-Luc
Brussels, Belgium, 1200